Fortis Healthcare Board Approves Q3 FY26 Results and New ESOP Scheme
Fortis Healthcare's Board approved Q3 FY26 results and a new ESOP 2026 scheme. The ESOP 2026 allows for the grant of 1,50,99,163 options, exercisable into equity shares of ₹10 face value. The exercise price will be the market price, not less than the face value. Revisions to the Related Party Transaction Policy were also approved.
The approval of financial results is routine, but the introduction of a new ESOP scheme can have a medium-term impact on employee motivation and potential dilution. The policy revision is also a significant internal governance change.
The approval of financial results and the introduction of an employee stock option scheme are generally viewed positively by the market as they indicate operational progress and a commitment to employee incentives.
Fortis Healthcare Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the un-audited standalone and consolidated financial results for the quarter and period ended December 31, 2025. Accompanying these results are the Limited Review Reports from the Statutory Auditors and certificates regarding financial covenants.
Furthermore, the Board, based on the recommendation of the Nomination and Remuneration Committee, approved the formulation and implementation of the "Fortis Healthcare Limited Employee Stock Option Scheme 2026" (ESOP 2026). This scheme is subject to shareholder and other necessary regulatory approvals and is in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulation, 2021. A pool of 1,50,99,163 employee stock options will be granted, each entitling the holder to one equity share of face value ₹10. The exercise price will be the market price on the grant date, not less than the face value, and vested options can be exercised within a maximum of four years from vesting.
The Board also approved revisions to the Related Party Transaction Policy. The Board Meeting commenced at 12:00 Hours (IST) and concluded at 18:40 Hours (IST).
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.